ログイン

Bone Pharm

Bone Pharm
77問 • 2年前
  • Two Clean Queens
  • 通報

    問題一覧

  • 1

    Preferred Bisphosphonates for Osteoporosis

    Alendronate, Risedronate, Zolendronic Acid

  • 2

    Suffix associated with Bisphosphonates

    -dronate

  • 3

    Bisphosphonates that treat post menopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget disease, as well as treatment of bone metastases and hypercalcemia of maligancy.

    Alendronate, Risedronate, Zoledronic Acid, Etidronate, Ibandronate, Pamidronate

  • 4

    Bind to hydroxyapatite in decrease Osteoclastic bone resorption causing small increase in bone mass and decrease risk of fractures

    Mechanism of Action for Bisphosphonates

  • 5

    A Bisphosphonate that where Beneficial effects increase exponentially over several years of therapy, but discontinuation needs to gradual loss of effects

    Alendronate

  • 6

    First Line Therapy for Paget’s Disease r/t high efficacy and once-yearly dosing. Has very high affinity for mineralized bone and decreases bone resorption up to 1 year after a single IV dose.

    Zolendronic Acid

  • 7

    Bisphosphonates that are dosed daily, weekly, or monthly depending on the drug.

    Alendronate, Risedronate, and Ibandronate

  • 8

    They are cleared rapidly from the plasma (r/t binding of hydroxyapatite). Once bound to bone, they are cleared via kidneys over a period of hours to years.

    Bisphosphonates

  • 9

    Patients unable to tolerate oral Bisphosphonates receive?

    Ibandronate or Zolendronic Acid IV

  • 10

    Contraindications of Bisphosphonates

    Avoid with severe renal impairment

  • 11

    Diarrhea, Abdominal and Musculoskeletal Pain are common side effects

    Bisphosphonates

  • 12

    Esophagitis and Esophageal Ulcers are common side effects

    Alendronate, Risedronate, Ibandronate

  • 13

    ONJ and Atypical Femur Fractures are uncommon adverse effects

    Bisphosphonates

  • 14

    Absorption is poor (<1%) and food and other medications interfere with its absorption

    Bisphosphonates

  • 15

    How much water should you take with Bisphosphonates?

    6-8 oz water only

  • 16

    How much water should you take with Risedronate ER?

    At least 4 oz of water only

  • 17

    How long should you remain upright after taking Bisphosphonates?

    At least 30 minutes

  • 18

    How long should you remain upright with Ibandronate?

    At least 60 minutes

  • 19

    Bisphosphonate that is taken orally (daily or weekly); effervescent tab (taken weekly)

    Alendronate

  • 20

    Bisphosphonate that is taken orally (monthly); IV (taken every 3 months)

    Ibandronate

  • 21

    Bisphosphonate that is taken yearly by IV

    Zolendronic Acid

  • 22

    How many years of Bisphosphonate oral therapy until a drug holiday?

    5 years

  • 23

    How many years of Bisphosphonate Zolendronic Acid IV therapy until a drug holiday?

    3 years

  • 24

    Bisphosphonate therapy should not be discontinued in women who are high risk of

    Fractures

  • 25

    Drugs that contribute to bone loss

    Aluminum antacids, Anticonvulsants (phenytoin), arommatase inhibitors, furosemide, glucocorticoids

  • 26

    Drugs that contribute to bone loss

    Heparin, medroxyprogesterone, PPIs, SSRIs, thiazolidinediones, thyroid (excessive)

  • 27

    Alternative first line RANKL for postmenopausal osteoporosis, particularly with patients with higher risk of fractures, and osteoporosis in men and glucocorticoid-induced osteoporosis

    Denosumab

  • 28

    Monoclonal antibody targets receptor activator of nuclear factor kappa-B ligand (RANKL). By binding to RANKL, it prevents activation of RANK receptors on onsteoclasts, thereby inhibiting osteoclast formation and reducing done resorption.

    Mechanism of action for Denosumab

  • 29

    GI upset, bone pain, increased risk of infection, skin reactions, hypocalcemia

    Common side effects of Denosumab

  • 30

    Adverse effects of Denosumab

    ONJ and atypical fractures

  • 31

    How is Denosumab administered?

    SQ injection every 6 months

  • 32

    Parathyroid agent that is a recombinant form of human parathyroid hormone

    Teriparatide

  • 33

    Analog of parathyroid hormone-related peptide

    Abalparatide

  • 34

    Acts as an agoinist at the parathyroid hormone receptor in stimulation of osteoclastic activity thereby increasing bone formation and strength

    Mechanism of action of Teriparatide and Abalparatide

  • 35

    Contraindications for Teriparatide and Abalparatide

    Patients at risk of osteosarcoma

  • 36

    Hyperuricemia can occur with?

    Abalparatide

  • 37

    Injection site reactions, hypercalcemia, and orthostatic hypotension

    Adverse drug reactions for Teriparatide and Abalparatide

  • 38

    Should be reserved for patients for high risk for fractures and those who have failed or cannot tolerate other osteoporosis therapies

    Parathyroid Agents

  • 39

    Cumulative therapy should not last more than 2 years, and following therapy another anti-resorptive agent for osteoporosis should be initiated to maintain bone density and prevent loss

    Parathyroid Agents

  • 40

    Monoclonal antibody and inhibitor of Sclerostin

    Romosozumab

  • 41

    Binds to Sclerostin (regulator factor that inhibits bone formation) and inhibits it’s action, thereby promoting osteoblast activity and bone formation. Secondry action - to decrease bone resorption.

    Romosozumab

  • 42

    Contraindications for Sclerostin Inhibitors

    Patients with a history of MI or stroke

  • 43

    Adverse drug effects include arthralgias, headache, and injection site reactions

    Romosozumab

  • 44

    Indicated for postmenopausal women at high risk of fractures. Two SQ injections are given yearly.

    Romosozumab

  • 45

    SERMs for postmenopausal women with osteoporosis

    Raloxifene and Bazedoxifene

  • 46

    Estrogen-like affects on bone and estrogen antagonist, affects on breast and endometrial tissue causing increases in bone density without increasing of endometrial cancer, and decreases risk of invasive breast cancer

    Mechanism of action for SERMs

  • 47

    Contraindications for SERMs

    Patients with a history of DVT and PE

  • 48

    Hot flashes, leg cramps, and increased risk of DVT

    Adverse drug effects for SERMs

  • 49

    Because it has not been shown to reduce non-vertebral or hip fractures, this drug should be used as an alternative for postmenopausal women who cannot take Bisphosphonates or Denosumab

    Raloxifene

  • 50

    Peptide secreted by the thyroid gland that binds to osteoclasts inhibits their resorptive activity thereby by reducing bone resorption

    Calcitonin

  • 51

    Rhinitis and injection site reactions are adverse reactions

    Calcitonin

  • 52

    Indicated for postmenopausal women who are at least five years postmenopausal but is less effective than other osteoporosis medications

    Calcitonin

  • 53

    Given intranasally or by injection (IM or SQ). For postmenopausal women who are at least 5 years postmenopausal. Is less effective than other osteoporosis medications, and should only be used if other agents not tolerated or appropriate. Has higher risk of new malignancy with long term use.

    Calcitonin

  • 54

    Suffix for Parathyroid Agents

    -paratide

  • 55

    Suffix for SERMs

    -oxifene

  • 56

    How is Risedronate delayed-release tablet taken?

    Immediately after breakfast

  • 57

    A 52-year old woman has a history of RA, DM, HTN, and heartburn. Her medications include methotrexate, prednisone, metformin, hydrochlorothiazide, lisiniopril and calcium carbonate. She is worried about the risk of osteoprosis as she approaches menopause. Which of her medications is most likely to contribute to the risk of developing osteoporosis?

    Prednisone

  • 58

    What are one of two criteria needed to be met for a diagnosis of osteoporosis?

    T-score </= -2.5 or history of fragility fracture

  • 59

    Which of the following is correct reguarding the pharmacokinetics of the bisphosphonates?

    Food or other medications greatly impair absorption of bisphosphonates

  • 60

    A 56 year old womand who has been diagnosed with postmenopausal ostoeporosis has no history of fractures and no other pertinent medical conditions. Which of the following is most appropriate for the management of her osteoporosis?

    Alendronate

  • 61

    A patient has been taking Alendronate for postmenopausal osteoporsis for 5 years with slight increase in bone mineral density and no occurrence of fracures. Risk of which adverse effect might warrant consideration of a drug holiday from Alendronate in this patient?

    Atypical femur fractures

  • 62

    Which of the following best describes the mechanism of action of Denosumab in the treatment of osteoporosis?

    RANKL inhibitor

  • 63

    Use of which agent for osteoporosis should be limited to no more than 2 years?

    Teriparatide

  • 64

    Which of the following characteristics would make a patient the most appropriate candidate for Abaloparatide treatment for postmenopausal osteoporosis?

    History of multiple vertebral fractures

  • 65

    A 55 year old man is diagnosed with Paget disease. He has no other significant medical history. Which agent would be most appropriate for treatment of Paget disease in this patient?

    Zoledronic Acid

  • 66

    A 67 year old woman complains of severe back pain and is found to have multiple verterbral fractures related to osteoporosis. The patient has a past medical history of HTN, CKD, and MI 6 months ago. Which of the following would exclude the use of Romosozumab in this patient?

    MI

  • 67

    A 55 year old woman with postmenopausal osteoporosis has a past medical history of alcohol use disorder, alcoholic liver disease, erosive esophagitis, and hypothyroidism. Which is the primary reason oral Bisphosphonates should be used with caution in this patient?

    Erosive esophagitis

  • 68

    45 year old African American woman who was a previous smoker has a BMI of 32 kg/m2. She is currently on a 1 week taper of Prednisone for an asthma flair. She is also taking Lisinopril 20 mg for HTN. Which of the following is associated with the most INCREASED risk for her developing osteoporosis in this patient?

    Female gender

  • 69

    72 y/o woman with a history of vertebral compression fracture and a DEXA T score of -2.7 in the left hip. What is the best initial therapy for this patient?

    Alendronate 70 mg weekly

  • 70

    75 y/o woman with newly diagnosed osteoporosis, being discharged after total hip replacement due to right hip fracture. She has never been medication for osteoporosis. PMH is significant for severe GERD, DVT [20 years ago], atrial fibrillation and family history of breast cancer. Which therapy may offer the MOST benefit in this patient?

    Denosumab 60 mg SQ every 6 months

  • 71

    68 y/o post menopausal woman with a history of T2DM, CAD, dyslipidemia, GERD, OA of knees, stage 3 CKD. Recent EGD was unremarkable. DEXA scan showed t score of -3 of the left hip. Which of the following precludes the used of a bisphosphonate?

    Renal disease

  • 72

    53 y/o woman with history of esophageal stricture—recently treated successfully with dilatation—from longstanding GERD, and vasomotor symptoms of menopause. A recent DEXA showed a T score of -2.5 of the LS spine and -2.6 in the left hip. Which therapy is MOST appropriate?

    Denosumab 60 mg SQ every 6 months

  • 73

    38 y/o woman who is at a health fair. She asks what she can do to maintain her bone health. Her mum had sever osteoporosis with vertebral fractures, spinal kyphosis, hip fracture and limited mobility. Your patient is 64 inches tall and weighs 115 pounds. She is postmenopausal. Her meds include OCP and a multivitamin daily; her DEXA scan shows a T score of -1.3 and a Z score of -.8. which exercise regimen is going to be most helpful to improve her bone health?

    Stair climbing and Running

  • 74

    68 y/o man with several risk factors for osteoporosis— cigarette smoking, drinking 3-5 alcoholic drinks/day, low body weight and sedentary lifestyle. Labs reveal a 25 Vitamin D level of 18 mcg. Of the following, what will you recommend?

    Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then 5,000 IU thereafter

  • 75

    Higher dose, longer duration of therapy, IV administration, dental extractions or implants, use of glucocorticoids, diabetes, and smoking put patients on bisphosphonates at increased risk for?

    ONJ

  • 76

    Long term use of bisphosphonates put patients at increased risk for?

    Atypical fractures

  • 77

    Preferred Bisphosphonates for Osteoporosis

    Alendronate, Risedronate, Zolendronic Acid

  • Patho Renal

    Patho Renal

    Two Clean Queens · 100問 · 2年前

    Patho Renal

    Patho Renal

    100問 • 2年前
    Two Clean Queens

    Pathophysiology

    Pathophysiology

    Two Clean Queens · 100問 · 2年前

    Pathophysiology

    Pathophysiology

    100問 • 2年前
    Two Clean Queens

    Patho Immunology

    Patho Immunology

    Two Clean Queens · 34問 · 2年前

    Patho Immunology

    Patho Immunology

    34問 • 2年前
    Two Clean Queens

    Patho Hematology

    Patho Hematology

    Two Clean Queens · 100問 · 2年前

    Patho Hematology

    Patho Hematology

    100問 • 2年前
    Two Clean Queens

    Patho Hematology 2

    Patho Hematology 2

    Two Clean Queens · 76問 · 2年前

    Patho Hematology 2

    Patho Hematology 2

    76問 • 2年前
    Two Clean Queens

    Patho Respiratory

    Patho Respiratory

    Two Clean Queens · 100問 · 2年前

    Patho Respiratory

    Patho Respiratory

    100問 • 2年前
    Two Clean Queens

    Patho Respiratory 2

    Patho Respiratory 2

    Two Clean Queens · 54問 · 2年前

    Patho Respiratory 2

    Patho Respiratory 2

    54問 • 2年前
    Two Clean Queens

    Patho Cardiovascular

    Patho Cardiovascular

    Two Clean Queens · 100問 · 2年前

    Patho Cardiovascular

    Patho Cardiovascular

    100問 • 2年前
    Two Clean Queens

    Patho Cardiovascular 2

    Patho Cardiovascular 2

    Two Clean Queens · 56問 · 2年前

    Patho Cardiovascular 2

    Patho Cardiovascular 2

    56問 • 2年前
    Two Clean Queens

    Patho MSK

    Patho MSK

    Two Clean Queens · 52問 · 2年前

    Patho MSK

    Patho MSK

    52問 • 2年前
    Two Clean Queens

    Patho Acid Base

    Patho Acid Base

    Two Clean Queens · 35問 · 2年前

    Patho Acid Base

    Patho Acid Base

    35問 • 2年前
    Two Clean Queens

    Renal 2

    Renal 2

    Two Clean Queens · 10問 · 2年前

    Renal 2

    Renal 2

    10問 • 2年前
    Two Clean Queens

    Fluid Balance

    Fluid Balance

    Two Clean Queens · 43問 · 2年前

    Fluid Balance

    Fluid Balance

    43問 • 2年前
    Two Clean Queens

    Patho Endocrine

    Patho Endocrine

    Two Clean Queens · 100問 · 2年前

    Patho Endocrine

    Patho Endocrine

    100問 • 2年前
    Two Clean Queens

    Patho Endocrine 2

    Patho Endocrine 2

    Two Clean Queens · 42問 · 2年前

    Patho Endocrine 2

    Patho Endocrine 2

    42問 • 2年前
    Two Clean Queens

    Infections

    Infections

    Two Clean Queens · 58問 · 2年前

    Infections

    Infections

    58問 • 2年前
    Two Clean Queens

    Patho Shock

    Patho Shock

    Two Clean Queens · 31問 · 2年前

    Patho Shock

    Patho Shock

    31問 • 2年前
    Two Clean Queens

    GI

    GI

    Two Clean Queens · 100問 · 2年前

    GI

    GI

    100問 • 2年前
    Two Clean Queens

    GI 2

    GI 2

    Two Clean Queens · 18問 · 2年前

    GI 2

    GI 2

    18問 • 2年前
    Two Clean Queens

    Cancer

    Cancer

    Two Clean Queens · 54問 · 2年前

    Cancer

    Cancer

    54問 • 2年前
    Two Clean Queens

    Neuro

    Neuro

    Two Clean Queens · 94問 · 2年前

    Neuro

    Neuro

    94問 • 2年前
    Two Clean Queens

    Psychopathology

    Psychopathology

    Two Clean Queens · 20問 · 2年前

    Psychopathology

    Psychopathology

    20問 • 2年前
    Two Clean Queens

    Urology Pharm

    Urology Pharm

    Two Clean Queens · 68問 · 2年前

    Urology Pharm

    Urology Pharm

    68問 • 2年前
    Two Clean Queens

    Lifestyle Considerations Outline_Pharm

    Lifestyle Considerations Outline_Pharm

    Two Clean Queens · 97問 · 2年前

    Lifestyle Considerations Outline_Pharm

    Lifestyle Considerations Outline_Pharm

    97問 • 2年前
    Two Clean Queens

    Prescribing Basics Outline_Pharm

    Prescribing Basics Outline_Pharm

    Two Clean Queens · 23問 · 2年前

    Prescribing Basics Outline_Pharm

    Prescribing Basics Outline_Pharm

    23問 • 2年前
    Two Clean Queens

    Pharmacokinetics_Pharm

    Pharmacokinetics_Pharm

    Two Clean Queens · 31問 · 2年前

    Pharmacokinetics_Pharm

    Pharmacokinetics_Pharm

    31問 • 2年前
    Two Clean Queens

    Diabetes Pharm

    Diabetes Pharm

    Two Clean Queens · 100問 · 2年前

    Diabetes Pharm

    Diabetes Pharm

    100問 • 2年前
    Two Clean Queens

    Diabetes Pharm 2

    Diabetes Pharm 2

    Two Clean Queens · 41問 · 2年前

    Diabetes Pharm 2

    Diabetes Pharm 2

    41問 • 2年前
    Two Clean Queens

    Neuroendocrine Obesity Pharm

    Neuroendocrine Obesity Pharm

    Two Clean Queens · 100問 · 2年前

    Neuroendocrine Obesity Pharm

    Neuroendocrine Obesity Pharm

    100問 • 2年前
    Two Clean Queens

    Neuroendocrine Obesity Pharm 2

    Neuroendocrine Obesity Pharm 2

    Two Clean Queens · 43問 · 2年前

    Neuroendocrine Obesity Pharm 2

    Neuroendocrine Obesity Pharm 2

    43問 • 2年前
    Two Clean Queens

    Dermatology Pharm

    Dermatology Pharm

    Two Clean Queens · 106問 · 1年前

    Dermatology Pharm

    Dermatology Pharm

    106問 • 1年前
    Two Clean Queens

    Dermatology Pharm 2

    Dermatology Pharm 2

    Two Clean Queens · 24問 · 1年前

    Dermatology Pharm 2

    Dermatology Pharm 2

    24問 • 1年前
    Two Clean Queens

    Cardiac/Renal Pharm 1

    Cardiac/Renal Pharm 1

    Two Clean Queens · 100問 · 1年前

    Cardiac/Renal Pharm 1

    Cardiac/Renal Pharm 1

    100問 • 1年前
    Two Clean Queens

    Cardiac/Renal Pharm 2

    Cardiac/Renal Pharm 2

    Two Clean Queens · 100問 · 1年前

    Cardiac/Renal Pharm 2

    Cardiac/Renal Pharm 2

    100問 • 1年前
    Two Clean Queens

    Cardiac/Renal Pharm 3

    Cardiac/Renal Pharm 3

    Two Clean Queens · 86問 · 1年前

    Cardiac/Renal Pharm 3

    Cardiac/Renal Pharm 3

    86問 • 1年前
    Two Clean Queens

    Anticoagulants Pharm

    Anticoagulants Pharm

    Two Clean Queens · 46問 · 1年前

    Anticoagulants Pharm

    Anticoagulants Pharm

    46問 • 1年前
    Two Clean Queens

    Herbals

    Herbals

    Two Clean Queens · 48問 · 1年前

    Herbals

    Herbals

    48問 • 1年前
    Two Clean Queens

    N5220 Exam Pearls

    N5220 Exam Pearls

    Two Clean Queens · 100問 · 1年前

    N5220 Exam Pearls

    N5220 Exam Pearls

    100問 • 1年前
    Two Clean Queens

    DRIQ

    DRIQ

    Two Clean Queens · 67問 · 1年前

    DRIQ

    DRIQ

    67問 • 1年前
    Two Clean Queens

    Clinical Pearls Test 2

    Clinical Pearls Test 2

    Two Clean Queens · 76問 · 1年前

    Clinical Pearls Test 2

    Clinical Pearls Test 2

    76問 • 1年前
    Two Clean Queens

    Test 2 Seidel's Part I

    Test 2 Seidel's Part I

    Two Clean Queens · 94問 · 1年前

    Test 2 Seidel's Part I

    Test 2 Seidel's Part I

    94問 • 1年前
    Two Clean Queens

    Test 2 Seidel's Part II

    Test 2 Seidel's Part II

    Two Clean Queens · 98問 · 1年前

    Test 2 Seidel's Part II

    Test 2 Seidel's Part II

    98問 • 1年前
    Two Clean Queens

    NURS 5112 Exam Review Part 1

    NURS 5112 Exam Review Part 1

    Two Clean Queens · 66問 · 1年前

    NURS 5112 Exam Review Part 1

    NURS 5112 Exam Review Part 1

    66問 • 1年前
    Two Clean Queens

    NURS 5140 Exam 1 Review Part 1

    NURS 5140 Exam 1 Review Part 1

    Two Clean Queens · 100問 · 1年前

    NURS 5140 Exam 1 Review Part 1

    NURS 5140 Exam 1 Review Part 1

    100問 • 1年前
    Two Clean Queens

    NURS 5140 Exam 1 Review Application Part 1

    NURS 5140 Exam 1 Review Application Part 1

    Two Clean Queens · 100問 · 1年前

    NURS 5140 Exam 1 Review Application Part 1

    NURS 5140 Exam 1 Review Application Part 1

    100問 • 1年前
    Two Clean Queens

    NURS 5410 Exam 1 ApplicationPart 2

    NURS 5410 Exam 1 ApplicationPart 2

    Two Clean Queens · 50問 · 1年前

    NURS 5410 Exam 1 ApplicationPart 2

    NURS 5410 Exam 1 ApplicationPart 2

    50問 • 1年前
    Two Clean Queens

    Exam 2 NURS 5140

    Exam 2 NURS 5140

    Two Clean Queens · 8問 · 1年前

    Exam 2 NURS 5140

    Exam 2 NURS 5140

    8問 • 1年前
    Two Clean Queens

    NURS 5112 Exam 2 ChatGPT

    NURS 5112 Exam 2 ChatGPT

    Two Clean Queens · 90問 · 1年前

    NURS 5112 Exam 2 ChatGPT

    NURS 5112 Exam 2 ChatGPT

    90問 • 1年前
    Two Clean Queens

    Exam 3 NURS 5410 Anxiety

    Exam 3 NURS 5410 Anxiety

    Two Clean Queens · 66問 · 1年前

    Exam 3 NURS 5410 Anxiety

    Exam 3 NURS 5410 Anxiety

    66問 • 1年前
    Two Clean Queens

    Exam 3 NURS 5410 Pain

    Exam 3 NURS 5410 Pain

    Two Clean Queens · 44問 · 1年前

    Exam 3 NURS 5410 Pain

    Exam 3 NURS 5410 Pain

    44問 • 1年前
    Two Clean Queens

    Exam 3 NURS 5410 Sleep

    Exam 3 NURS 5410 Sleep

    Two Clean Queens · 72問 · 1年前

    Exam 3 NURS 5410 Sleep

    Exam 3 NURS 5410 Sleep

    72問 • 1年前
    Two Clean Queens

    NURS 5410 Exam 3 Quizzes

    NURS 5410 Exam 3 Quizzes

    Two Clean Queens · 25問 · 1年前

    NURS 5410 Exam 3 Quizzes

    NURS 5410 Exam 3 Quizzes

    25問 • 1年前
    Two Clean Queens

    Psychopharm Exam 1

    Psychopharm Exam 1

    Two Clean Queens · 71問 · 1年前

    Psychopharm Exam 1

    Psychopharm Exam 1

    71問 • 1年前
    Two Clean Queens

    Gero Psych Exam 1

    Gero Psych Exam 1

    Two Clean Queens · 62問 · 1年前

    Gero Psych Exam 1

    Gero Psych Exam 1

    62問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 1)

    Psychopharmacology Exam 2 (part 1)

    Two Clean Queens · 19問 · 1年前

    Psychopharmacology Exam 2 (part 1)

    Psychopharmacology Exam 2 (part 1)

    19問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 1)

    Peds Psych Exam 2 (part 1)

    Two Clean Queens · 19問 · 1年前

    Peds Psych Exam 2 (part 1)

    Peds Psych Exam 2 (part 1)

    19問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 2)

    Peds Psych Exam 2 (part 2)

    Two Clean Queens · 50問 · 1年前

    Peds Psych Exam 2 (part 2)

    Peds Psych Exam 2 (part 2)

    50問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 3)

    Peds Psych Exam 2 (part 3)

    Two Clean Queens · 67問 · 1年前

    Peds Psych Exam 2 (part 3)

    Peds Psych Exam 2 (part 3)

    67問 • 1年前
    Two Clean Queens

    Peds Psych Exam 2 (part 4)

    Peds Psych Exam 2 (part 4)

    Two Clean Queens · 20問 · 1年前

    Peds Psych Exam 2 (part 4)

    Peds Psych Exam 2 (part 4)

    20問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 2)

    Psychopharmacology Exam 2 (part 2)

    Two Clean Queens · 80問 · 1年前

    Psychopharmacology Exam 2 (part 2)

    Psychopharmacology Exam 2 (part 2)

    80問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 3)

    Psychopharmacology Exam 2 (part 3)

    Two Clean Queens · 46問 · 1年前

    Psychopharmacology Exam 2 (part 3)

    Psychopharmacology Exam 2 (part 3)

    46問 • 1年前
    Two Clean Queens

    Psychopharmacology Exam 2 (part 4)

    Psychopharmacology Exam 2 (part 4)

    Two Clean Queens · 22問 · 1年前

    Psychopharmacology Exam 2 (part 4)

    Psychopharmacology Exam 2 (part 4)

    22問 • 1年前
    Two Clean Queens

    Psychopharm Depressive Disorders

    Psychopharm Depressive Disorders

    Two Clean Queens · 86問 · 11ヶ月前

    Psychopharm Depressive Disorders

    Psychopharm Depressive Disorders

    86問 • 11ヶ月前
    Two Clean Queens

    Psychopharm Bipolar Disorder

    Psychopharm Bipolar Disorder

    Two Clean Queens · 58問 · 11ヶ月前

    Psychopharm Bipolar Disorder

    Psychopharm Bipolar Disorder

    58問 • 11ヶ月前
    Two Clean Queens

    Psychopharm Anxiety Disorders

    Psychopharm Anxiety Disorders

    Two Clean Queens · 32問 · 11ヶ月前

    Psychopharm Anxiety Disorders

    Psychopharm Anxiety Disorders

    32問 • 11ヶ月前
    Two Clean Queens

    Child Psych Anxiety

    Child Psych Anxiety

    Two Clean Queens · 56問 · 11ヶ月前

    Child Psych Anxiety

    Child Psych Anxiety

    56問 • 11ヶ月前
    Two Clean Queens

    Child Psych OCD/Gen Dysph

    Child Psych OCD/Gen Dysph

    Two Clean Queens · 34問 · 11ヶ月前

    Child Psych OCD/Gen Dysph

    Child Psych OCD/Gen Dysph

    34問 • 11ヶ月前
    Two Clean Queens

    Child Psych Eating Disorders 1

    Child Psych Eating Disorders 1

    Two Clean Queens · 49問 · 11ヶ月前

    Child Psych Eating Disorders 1

    Child Psych Eating Disorders 1

    49問 • 11ヶ月前
    Two Clean Queens

    Child Psych Eating Disorders 2

    Child Psych Eating Disorders 2

    Two Clean Queens · 14問 · 11ヶ月前

    Child Psych Eating Disorders 2

    Child Psych Eating Disorders 2

    14問 • 11ヶ月前
    Two Clean Queens

    Gero Mood Disorders

    Gero Mood Disorders

    Two Clean Queens · 19問 · 11ヶ月前

    Gero Mood Disorders

    Gero Mood Disorders

    19問 • 11ヶ月前
    Two Clean Queens

    Gero Anxiety Disorders

    Gero Anxiety Disorders

    Two Clean Queens · 13問 · 11ヶ月前

    Gero Anxiety Disorders

    Gero Anxiety Disorders

    13問 • 11ヶ月前
    Two Clean Queens

    Gero OCD & PTSD

    Gero OCD & PTSD

    Two Clean Queens · 15問 · 11ヶ月前

    Gero OCD & PTSD

    Gero OCD & PTSD

    15問 • 11ヶ月前
    Two Clean Queens

    Psychopharm Sleep

    Psychopharm Sleep

    Two Clean Queens · 34問 · 10ヶ月前

    Psychopharm Sleep

    Psychopharm Sleep

    34問 • 10ヶ月前
    Two Clean Queens

    Psychopharm ADHD

    Psychopharm ADHD

    Two Clean Queens · 20問 · 10ヶ月前

    Psychopharm ADHD

    Psychopharm ADHD

    20問 • 10ヶ月前
    Two Clean Queens

    Psychopharm Eating Disorders

    Psychopharm Eating Disorders

    Two Clean Queens · 6問 · 10ヶ月前

    Psychopharm Eating Disorders

    Psychopharm Eating Disorders

    6問 • 10ヶ月前
    Two Clean Queens

    Psychopharm Reward and Pleasure

    Psychopharm Reward and Pleasure

    Two Clean Queens · 32問 · 10ヶ月前

    Psychopharm Reward and Pleasure

    Psychopharm Reward and Pleasure

    32問 • 10ヶ月前
    Two Clean Queens

    Psychopharm Impulsivity/Compulsvity/Addiction

    Psychopharm Impulsivity/Compulsvity/Addiction

    Two Clean Queens · 7問 · 10ヶ月前

    Psychopharm Impulsivity/Compulsvity/Addiction

    Psychopharm Impulsivity/Compulsvity/Addiction

    7問 • 10ヶ月前
    Two Clean Queens

    Gero Exam 4 Review

    Gero Exam 4 Review

    Two Clean Queens · 81問 · 10ヶ月前

    Gero Exam 4 Review

    Gero Exam 4 Review

    81問 • 10ヶ月前
    Two Clean Queens

    Child Psych Sleep/Wake Disorders

    Child Psych Sleep/Wake Disorders

    Two Clean Queens · 58問 · 10ヶ月前

    Child Psych Sleep/Wake Disorders

    Child Psych Sleep/Wake Disorders

    58問 • 10ヶ月前
    Two Clean Queens

    Child Psych ODD/CD/SUD

    Child Psych ODD/CD/SUD

    Two Clean Queens · 49問 · 10ヶ月前

    Child Psych ODD/CD/SUD

    Child Psych ODD/CD/SUD

    49問 • 10ヶ月前
    Two Clean Queens

    問題一覧

  • 1

    Preferred Bisphosphonates for Osteoporosis

    Alendronate, Risedronate, Zolendronic Acid

  • 2

    Suffix associated with Bisphosphonates

    -dronate

  • 3

    Bisphosphonates that treat post menopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget disease, as well as treatment of bone metastases and hypercalcemia of maligancy.

    Alendronate, Risedronate, Zoledronic Acid, Etidronate, Ibandronate, Pamidronate

  • 4

    Bind to hydroxyapatite in decrease Osteoclastic bone resorption causing small increase in bone mass and decrease risk of fractures

    Mechanism of Action for Bisphosphonates

  • 5

    A Bisphosphonate that where Beneficial effects increase exponentially over several years of therapy, but discontinuation needs to gradual loss of effects

    Alendronate

  • 6

    First Line Therapy for Paget’s Disease r/t high efficacy and once-yearly dosing. Has very high affinity for mineralized bone and decreases bone resorption up to 1 year after a single IV dose.

    Zolendronic Acid

  • 7

    Bisphosphonates that are dosed daily, weekly, or monthly depending on the drug.

    Alendronate, Risedronate, and Ibandronate

  • 8

    They are cleared rapidly from the plasma (r/t binding of hydroxyapatite). Once bound to bone, they are cleared via kidneys over a period of hours to years.

    Bisphosphonates

  • 9

    Patients unable to tolerate oral Bisphosphonates receive?

    Ibandronate or Zolendronic Acid IV

  • 10

    Contraindications of Bisphosphonates

    Avoid with severe renal impairment

  • 11

    Diarrhea, Abdominal and Musculoskeletal Pain are common side effects

    Bisphosphonates

  • 12

    Esophagitis and Esophageal Ulcers are common side effects

    Alendronate, Risedronate, Ibandronate

  • 13

    ONJ and Atypical Femur Fractures are uncommon adverse effects

    Bisphosphonates

  • 14

    Absorption is poor (<1%) and food and other medications interfere with its absorption

    Bisphosphonates

  • 15

    How much water should you take with Bisphosphonates?

    6-8 oz water only

  • 16

    How much water should you take with Risedronate ER?

    At least 4 oz of water only

  • 17

    How long should you remain upright after taking Bisphosphonates?

    At least 30 minutes

  • 18

    How long should you remain upright with Ibandronate?

    At least 60 minutes

  • 19

    Bisphosphonate that is taken orally (daily or weekly); effervescent tab (taken weekly)

    Alendronate

  • 20

    Bisphosphonate that is taken orally (monthly); IV (taken every 3 months)

    Ibandronate

  • 21

    Bisphosphonate that is taken yearly by IV

    Zolendronic Acid

  • 22

    How many years of Bisphosphonate oral therapy until a drug holiday?

    5 years

  • 23

    How many years of Bisphosphonate Zolendronic Acid IV therapy until a drug holiday?

    3 years

  • 24

    Bisphosphonate therapy should not be discontinued in women who are high risk of

    Fractures

  • 25

    Drugs that contribute to bone loss

    Aluminum antacids, Anticonvulsants (phenytoin), arommatase inhibitors, furosemide, glucocorticoids

  • 26

    Drugs that contribute to bone loss

    Heparin, medroxyprogesterone, PPIs, SSRIs, thiazolidinediones, thyroid (excessive)

  • 27

    Alternative first line RANKL for postmenopausal osteoporosis, particularly with patients with higher risk of fractures, and osteoporosis in men and glucocorticoid-induced osteoporosis

    Denosumab

  • 28

    Monoclonal antibody targets receptor activator of nuclear factor kappa-B ligand (RANKL). By binding to RANKL, it prevents activation of RANK receptors on onsteoclasts, thereby inhibiting osteoclast formation and reducing done resorption.

    Mechanism of action for Denosumab

  • 29

    GI upset, bone pain, increased risk of infection, skin reactions, hypocalcemia

    Common side effects of Denosumab

  • 30

    Adverse effects of Denosumab

    ONJ and atypical fractures

  • 31

    How is Denosumab administered?

    SQ injection every 6 months

  • 32

    Parathyroid agent that is a recombinant form of human parathyroid hormone

    Teriparatide

  • 33

    Analog of parathyroid hormone-related peptide

    Abalparatide

  • 34

    Acts as an agoinist at the parathyroid hormone receptor in stimulation of osteoclastic activity thereby increasing bone formation and strength

    Mechanism of action of Teriparatide and Abalparatide

  • 35

    Contraindications for Teriparatide and Abalparatide

    Patients at risk of osteosarcoma

  • 36

    Hyperuricemia can occur with?

    Abalparatide

  • 37

    Injection site reactions, hypercalcemia, and orthostatic hypotension

    Adverse drug reactions for Teriparatide and Abalparatide

  • 38

    Should be reserved for patients for high risk for fractures and those who have failed or cannot tolerate other osteoporosis therapies

    Parathyroid Agents

  • 39

    Cumulative therapy should not last more than 2 years, and following therapy another anti-resorptive agent for osteoporosis should be initiated to maintain bone density and prevent loss

    Parathyroid Agents

  • 40

    Monoclonal antibody and inhibitor of Sclerostin

    Romosozumab

  • 41

    Binds to Sclerostin (regulator factor that inhibits bone formation) and inhibits it’s action, thereby promoting osteoblast activity and bone formation. Secondry action - to decrease bone resorption.

    Romosozumab

  • 42

    Contraindications for Sclerostin Inhibitors

    Patients with a history of MI or stroke

  • 43

    Adverse drug effects include arthralgias, headache, and injection site reactions

    Romosozumab

  • 44

    Indicated for postmenopausal women at high risk of fractures. Two SQ injections are given yearly.

    Romosozumab

  • 45

    SERMs for postmenopausal women with osteoporosis

    Raloxifene and Bazedoxifene

  • 46

    Estrogen-like affects on bone and estrogen antagonist, affects on breast and endometrial tissue causing increases in bone density without increasing of endometrial cancer, and decreases risk of invasive breast cancer

    Mechanism of action for SERMs

  • 47

    Contraindications for SERMs

    Patients with a history of DVT and PE

  • 48

    Hot flashes, leg cramps, and increased risk of DVT

    Adverse drug effects for SERMs

  • 49

    Because it has not been shown to reduce non-vertebral or hip fractures, this drug should be used as an alternative for postmenopausal women who cannot take Bisphosphonates or Denosumab

    Raloxifene

  • 50

    Peptide secreted by the thyroid gland that binds to osteoclasts inhibits their resorptive activity thereby by reducing bone resorption

    Calcitonin

  • 51

    Rhinitis and injection site reactions are adverse reactions

    Calcitonin

  • 52

    Indicated for postmenopausal women who are at least five years postmenopausal but is less effective than other osteoporosis medications

    Calcitonin

  • 53

    Given intranasally or by injection (IM or SQ). For postmenopausal women who are at least 5 years postmenopausal. Is less effective than other osteoporosis medications, and should only be used if other agents not tolerated or appropriate. Has higher risk of new malignancy with long term use.

    Calcitonin

  • 54

    Suffix for Parathyroid Agents

    -paratide

  • 55

    Suffix for SERMs

    -oxifene

  • 56

    How is Risedronate delayed-release tablet taken?

    Immediately after breakfast

  • 57

    A 52-year old woman has a history of RA, DM, HTN, and heartburn. Her medications include methotrexate, prednisone, metformin, hydrochlorothiazide, lisiniopril and calcium carbonate. She is worried about the risk of osteoprosis as she approaches menopause. Which of her medications is most likely to contribute to the risk of developing osteoporosis?

    Prednisone

  • 58

    What are one of two criteria needed to be met for a diagnosis of osteoporosis?

    T-score </= -2.5 or history of fragility fracture

  • 59

    Which of the following is correct reguarding the pharmacokinetics of the bisphosphonates?

    Food or other medications greatly impair absorption of bisphosphonates

  • 60

    A 56 year old womand who has been diagnosed with postmenopausal ostoeporosis has no history of fractures and no other pertinent medical conditions. Which of the following is most appropriate for the management of her osteoporosis?

    Alendronate

  • 61

    A patient has been taking Alendronate for postmenopausal osteoporsis for 5 years with slight increase in bone mineral density and no occurrence of fracures. Risk of which adverse effect might warrant consideration of a drug holiday from Alendronate in this patient?

    Atypical femur fractures

  • 62

    Which of the following best describes the mechanism of action of Denosumab in the treatment of osteoporosis?

    RANKL inhibitor

  • 63

    Use of which agent for osteoporosis should be limited to no more than 2 years?

    Teriparatide

  • 64

    Which of the following characteristics would make a patient the most appropriate candidate for Abaloparatide treatment for postmenopausal osteoporosis?

    History of multiple vertebral fractures

  • 65

    A 55 year old man is diagnosed with Paget disease. He has no other significant medical history. Which agent would be most appropriate for treatment of Paget disease in this patient?

    Zoledronic Acid

  • 66

    A 67 year old woman complains of severe back pain and is found to have multiple verterbral fractures related to osteoporosis. The patient has a past medical history of HTN, CKD, and MI 6 months ago. Which of the following would exclude the use of Romosozumab in this patient?

    MI

  • 67

    A 55 year old woman with postmenopausal osteoporosis has a past medical history of alcohol use disorder, alcoholic liver disease, erosive esophagitis, and hypothyroidism. Which is the primary reason oral Bisphosphonates should be used with caution in this patient?

    Erosive esophagitis

  • 68

    45 year old African American woman who was a previous smoker has a BMI of 32 kg/m2. She is currently on a 1 week taper of Prednisone for an asthma flair. She is also taking Lisinopril 20 mg for HTN. Which of the following is associated with the most INCREASED risk for her developing osteoporosis in this patient?

    Female gender

  • 69

    72 y/o woman with a history of vertebral compression fracture and a DEXA T score of -2.7 in the left hip. What is the best initial therapy for this patient?

    Alendronate 70 mg weekly

  • 70

    75 y/o woman with newly diagnosed osteoporosis, being discharged after total hip replacement due to right hip fracture. She has never been medication for osteoporosis. PMH is significant for severe GERD, DVT [20 years ago], atrial fibrillation and family history of breast cancer. Which therapy may offer the MOST benefit in this patient?

    Denosumab 60 mg SQ every 6 months

  • 71

    68 y/o post menopausal woman with a history of T2DM, CAD, dyslipidemia, GERD, OA of knees, stage 3 CKD. Recent EGD was unremarkable. DEXA scan showed t score of -3 of the left hip. Which of the following precludes the used of a bisphosphonate?

    Renal disease

  • 72

    53 y/o woman with history of esophageal stricture—recently treated successfully with dilatation—from longstanding GERD, and vasomotor symptoms of menopause. A recent DEXA showed a T score of -2.5 of the LS spine and -2.6 in the left hip. Which therapy is MOST appropriate?

    Denosumab 60 mg SQ every 6 months

  • 73

    38 y/o woman who is at a health fair. She asks what she can do to maintain her bone health. Her mum had sever osteoporosis with vertebral fractures, spinal kyphosis, hip fracture and limited mobility. Your patient is 64 inches tall and weighs 115 pounds. She is postmenopausal. Her meds include OCP and a multivitamin daily; her DEXA scan shows a T score of -1.3 and a Z score of -.8. which exercise regimen is going to be most helpful to improve her bone health?

    Stair climbing and Running

  • 74

    68 y/o man with several risk factors for osteoporosis— cigarette smoking, drinking 3-5 alcoholic drinks/day, low body weight and sedentary lifestyle. Labs reveal a 25 Vitamin D level of 18 mcg. Of the following, what will you recommend?

    Vitamin D3 [Calcitriol] 0.5 mcg daily for 8 weeks, then 5,000 IU thereafter

  • 75

    Higher dose, longer duration of therapy, IV administration, dental extractions or implants, use of glucocorticoids, diabetes, and smoking put patients on bisphosphonates at increased risk for?

    ONJ

  • 76

    Long term use of bisphosphonates put patients at increased risk for?

    Atypical fractures

  • 77

    Preferred Bisphosphonates for Osteoporosis

    Alendronate, Risedronate, Zolendronic Acid